Deciphera Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Deciphera Pharmaceuticals, Inc.
An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.
Recent submissions include what could be the fourth novel agent approved under the RTOR pilot.
Qinlock (ripretinib), approved as the US FDA rejected Blueprint Medicines’ Ayvakit (avapritinib) in the same indication, is priced on par with the rival drug cleared in January for a narrower GIST use.
Keeping Track: Good News For Deciphera, BMS And Clovis; Bad News For bluebird/BMS, Blueprint And Tonix
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
- Other Names / Subsidiaries
- Deciphera Pharmaceuticals, LLC